UPCOMING SESSIONS in ET
Tue, Jun 9, 2026
5:00 – 6:00 AM Bangkok
What is a care team and how to build one that works for you? Elizabeth Hushka Click Here To Register
UPCOMING SESSIONS in ET
Tue, Jun 9, 2026 · 5:00 – 6:00 AM Bangkok
What is a care team and how to build one that works for you?
Elizabeth Hushka
Click Here To Register
View all sessions

AMVUTTRA/Vutrisiran (ALN-TTRSC02)

accesshealth.png
Jun 28, 2023
Access Health: hATTR Amyloidosis Episode
As part of their continued dedication to raising awareness about hATTR amyloidosis and the impact the disease has on those affected, Alnylam Pharmaceuticals is…
Read more
Alnylam Rare Disease
Alnylam® Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi)…
Read more
AMVUTTRA_logo.jpg
Alnylam Announces FDA Approval of AMVUTTRA™ (Vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA(tm) (vutrisiran…
Read more
Logo_Alnylam_460-1.png
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of…
Read more
Logo_Alnylam_460-1.png
Alnylam Reports Positive Topline 18-Month Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi…
Read more
Subscribe to